Nur77 and Nor1 are highly conserved orphan nuclear receptors. We have recently reported that nur77 À / À nor1 À / À mice rapidly develop acute myeloid leukemia (AML) and that Nur77 and Nor1 transcripts were universally downregulated in human AML blasts. These findings indicate that Nur77 and Nor1 function as leukemia suppressors. We further demonstrated silencing of Nur77 and Nor1 in leukemia stem cells (LSCs). We here report that inhibition of histone deacetylase (HDAC) using the specific class I HDAC inhibitor SNDX-275 restored the expression of Nur77/Nor1 and induced expression of activator protein 1 transcription factors c-Jun and JunB, and of death receptor TRAIL, in AML cells and in CD34 þ /38 À AML LSCs. Importantly, SNDX-275 induced extensive apoptosis in AML cells, which could be suppressed by silencing nur77 and nor1. In addition, pro-apoptotic proteins Bim and Noxa were transcriptionally upregulated by SNDX-275 in AML cells and in LSCs. Our present work is the first report of a novel mechanism of HDAC inhibitor-induced apoptosis in AML that involves restoration of the silenced nuclear receptors Nur77 and Nor1, activation of activator protein 1 transcription factors, a death receptor and pro-apoptotic proteins.
INTRODUCTION
Acute myeloid leukemia (AML) arises from the clonal expansion of aberrant myeloid progenitor cells; their increased proliferation and failure to differentiate results in an accumulation of myeloblasts. Only one-third of younger adult patients diagnosed with AML can be cured, whereas older patients experience even lower survival rates.
1 Although many preclinical and clinical studies have sought to elucidate the biological and molecular basis of AML, the mechanism of AML pathogenesis remains undefined in the majority of cases. Recently, we reported that mice deficient in Nur77 and Nor1 develop AML-like disease and that reduced gene dosage of Nur77 and Nor1 leads to mixed myelodysplastic/ myeloproliferative neoplasms with progression to AML in rare cases. 2, 3 Orphan nuclear receptors Nur77 (also termed NR4A1, TR3 or NGFI-B) and Nor1 (also termed NR4A3 or MINOR) are highly conserved members of the nuclear receptor family. As transcription factors, they are involved in various physiological and cellular functions, including apoptosis, mitosis, inflammation and differentiation. [4] [5] [6] [7] Induction and activation of Nur77 and/or Nor1 have central roles in negative selection of T lymphocytes, macrophage activation-induced cell death and apoptosis induced by antineoplastic agents in various cancer cells. 5, [8] [9] [10] [11] Consistent with the parallel functions of these transcription factors, mice deficient in either nur77 or nor1 display relatively subtle abnormalities, 12 ,13 whereas mice deficient in both genes develop rapidly lethal and transplantable AML. 2 Importantly, the expression of Nur77 and Nor1 transcripts was profoundly decreased in leukemic blasts from all AML patients studied, compared with the levels in normal bone marrow cells, regardless of cytogenetics. 2 This finding suggests that silencing of Nur77 and Nor1 is a critical step in the pathogenesis of AML. Nur77 and Nor1 share 90% homology in the DNA-binding domain and they can both bind as monomers to a consensus NGFI-B response element sequence, or as homodimers to Nur-responsive element, 14, 15 hence sharing a set of common target genes. Nur77 has been shown to regulate the induction of Fas-L, TRAIL and pro-opiomelanocortin in lymphocytes or endocrine cells; 16, 17 however, the common targets of Nur77 and Nor1 are not well characterized. Molecular analysis of nur77 À / À / nor1 À / À mice revealed that the absence of both nur77 and nor1 was associated with downregulation of the activator protein 1 transcription factors c-Jun and JunB and downregulation of the extrinsic apoptosis inducers TRAIL and Fas-L in myeloid leukemia cells. 2 Epigenetic modifications have been shown to have critical roles in regulating gene expression. 18 Human tumor cells, including leukemia cells, exhibit a global loss of monoacetylation of histone H4, and aberrant histone acetyltransferase (HAT) and/or histone deacetylase (HDAC) activity has been shown to be associated with cancer development [19] [20] [21] [22] and hematological malignancies. [23] [24] [25] [26] [27] HDAC inhibitors display selective antitumor activity by inducing apoptosis, growth arrest and differentiation and induce the expression of cell-cycle inhibitors p21, p19 and p57 and of the pro-apoptotic gene TRAIL in leukemia cells. [28] [29] [30] [31] 28, [32] [33] [34] We hypothesized that histone acetylation has a role in gene silencing of Nur77/Nor1 and HDAC inhibitor SNDX-275 was used in our study. SNDX-275 (Entinostat), a synthetic benzamide derivative, selectively inhibits the activities of class I HDACs (HDAC1, 2 and 3), 35 has shown impressive efficacy in vitro and in vivo against a variety of tumors and is currently in phase I/II clinical trials. 35 In this study, we demonstrate that Nur77 and Nor1 are profoundly silenced not only in bulk leukemia cells but also in leukemia stem cells (LSCs). This silencing was largely reversed by the HDAC inhibitor SNDX-275 alone or in combination with another Nur77/Nor1 inducer ionomycin. The restoration of Nur77/ Nor1 by SNDX-275 was accompanied by upregulation of c-Jun, JunB, TRAIL, Bim and Noxa in AML cells and LSCs. This resulted in extensive apoptosis of bulk AML and LSCs.
MATERIALS AND METHODS
Chemicals and cell cultures SNDX-275 (Entinostat) was kindly provided by Dr. Peter Ordentlich (Syndax Pharmaceuticals, Inc., Waltham, MA, USA). Trichostatin A, suberoylanilide hydroxamic acid, depsipeptide (FK228) and ionomycin were purchased from Sigma-Aldrich (St Louis, MO, USA), Aton Pharma (Lawrenceville, NY, USA) and Fujisawa Pharmaceutical Co. Ltd (Osaka, Japan), respectively. AML cell lines HL-60, MOLM13, OCI-AML3 and OCI-AML2 were purchased from ATCC (Manassas, VA, USA). Bone marrow or peripheral blood samples were obtained consecutively for in vitro studies from patients diagnosed with AML during routine diagnostic workup under informed consent in accordance with regulations and protocols approved by the Institutional Review Board Committee of the University of Texas M. D. Anderson Cancer Center. Primary AML samples were harvested and no selection criteria were applied. Patient information is listed in Table 1 . Mononuclear cells were separated with lymphocyte separation media (Mediatech, Manassas, VA, USA) by density-gradient centrifugation resulting in 490% pure blast populations. Both cell lines and AML blast cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (HyClone, Logan, UT, USA), 1 mmol/l L-glutamine and 50 mg/ml penicillin/streptomycin.
Flow cytometry
The viable cell number (AnnV À /PI À , million/ml) and the % apoptosis (AnnV þ %, including AnnV þ /PI þ and AnnV þ /PI À ) in drug-treated samples were determined by using annexin V-FITC (BD Biosciences, San Jose, CA, USA) and propidium iodide (Sigma-Aldrich) as reported 36 and were used to calculate % surviving cells and % specific apoptosis. % surviving cells ¼ viable cell number in treated sample Â 100/viable cell number in control sample. % specific apoptosis
. 37 The number of surviving LSCs from primary patient samples was determined using a method described previously. 36 HDAC inhibitor SNDX-275 induces apoptosis in AML L Zhou et al leukemic cells was carried out by electroporation using the Amaxa Nucleofection system (Lonza, Cologne, Germany) following the manufacturer's instructions.
Chromatin immunoprecipitation
Chromatin immunoprecipitation assays were conducted using the enzymatic ChIP Kit (Cell Signaling 9002) according to the manufacturer's instructions. Primers amplifying human Nur77 and Nor1 promoters were:
0 . An aliquot of chromatin that was not incubated with an antibody was used as the input control sample (Input).
Statistics
Unless otherwise indicated, results are expressed as mean ± s.d. of three independent experiments. For immunoblot analyses, a representative immunoblot from three independent experiments is shown. P-values were determined by one-way ANOVA followed by F statistics. A P-value o0.05 was considered significant.
RESULTS

HDAC inhibitor SNDX-275 restores Nur77 and Nor1 expression
First, we determined the universal histone acetylation level changed by SNDX-275. By immunoblotting, both Ac-H3 and Ac-H4 were strongly increased at 24 h at nontoxic concentrations of promoters. An aliquot of chromatin that was not incubated with an antibody was used as the input control sample (Input). Chromatin incubated with rabbit serum was used as negative control (IgG).
Ac-H3
Ac (0) or indicated concentrations of SNDX-275 for 24 h and subjected to western blotting utilizing antibodies against acetyle-histone H4 (Ac-H4), histone H4 (H4), acetyle-histone H3 (Ac-H3) and histone H3 (H3). Beta-actin was used as a loading control. Because of limited sample size, effects on Ac-H4/totalH4 only were assessed in primary AML blasts.
SNDX-275, whereas total H3 and H4 levels were not affected ( Figure 1 ). H4 acetylation was also observed in primary AML samples. At concentrations activating histone acetylation, SNDX-275 strongly induced gene expression of Nur77 and Nor1 in a dose-dependent manner in AML cell lines HL-60, MOLM13, OCI-AML3 and OCI-AML2 (Figures 2ai and iii) . Importantly, SNDX-275 likewise restored Nur77 and Nor1 expression in primary AML blasts, although the increase was variable between different samples (Figures 2aii and iv) . In addition, three other HDAC inhibitors trichostatin A, suberoylanilide hydroxamic acid and FK228 displayed effective gene induction and all of them induced robust restoration of both Nur77 and Nor1 at sub-cytotoxic concentrations (Figure 2b ). Chromatin immunoprecipitation assays were performed to assess the acetylation levels of H4 on promoters of Nur77 and Nor1. Results demonstrated that SNDX-275 enhanced the amount of Ac-H4 on the promoter of Nur77 and Nor1, suggesting that SNDX-275 mediated the hyperacetylation of H4, which represents an active transcription status (Figure 2c ). These results indicate that histone deacetylation has a role in the epigenetic regulation of gene SNDX-275 induces Nur77-and Nor1-dependent apoptosis The pro-apoptotic activity of SNDX-275 in human leukemia cell lines and AML blasts has been demonstrated by Grant and colleagues. 31 Consistently, we observed that SNDX-275 induced extensive apoptosis in AML cell lines and primary samples in a time-and dose-dependent manner (Figure 4 and Supplementary  Figure 1) . To determine the role of Nur77/Nor1 in SNDX-275-induced apoptosis, gene silencing with siRNAs was conducted on HL-60 (with the best electroporation efficiency and tolerance among AML cell lines) and primary AML samples. siRNAs successfully reduced the level of Nur77/Nor1 (Figure 5a ). Double silencing of nur77 and nor1 significantly reduced apoptosis induction by SNDX-275 (Figure 5cii) , and attenuated the cell survival-inhibitory effects of SNDX-275 (Figure 5ci) , whereas silencing of a single gene was insufficient to suppress apoptosis. In primary AML samples, SNDX-275-induced reduction in cell numbers and apoptosis were significantly attenuated by the double silencing (Figures 5d-f , panels iii and iv, Supplementary  Figures 3A-C) . Simultaneously, samples with nur77/nor1 siRNA silencing were used for gene-expression analysis of Nur77/Nor1 hypothetical target genes. Double silencing of nur77 and nor1 led to a significant but only partial decrease of SNDX-275-induced c-Jun and JunB upregulation (Figure 5b ). At variance with the results in HL-60 cells, silencing of nur77 and nor1 diminished SNDX-275-induced upregulation of c-Jun and JunB only in the AML11 sample, but not in other two samples ( Supplementary  Figures 3D-F) . The SNDX-275-induced TRAIL upregulation was not significantly affected by silencing nur77 and nor1 in HL-60 and primary samples (Supplementary Figures 2Bi and 3D-F) . This result suggested that these genes may not be the direct targets of Nur77/Nor1.
We next sought to determine whether activation of Nur77/Nor1 through mechanisms other than HDAC blockade will promote apoptosis in AML cells. Calcium ionophore ionomycin and TPA are well-recognized inducers of Nur77 and Nor1 whose pulse stimulation leads to apoptosis in lymphocytes and thymocytes. 38 In HL-60 cells, 6-h exposure to ionomycin or TPA (data not shown) induced brisk upregulation of Nur77 and Nor1 proteins (Figure 6a ), followed by apoptosis at 48 h (Figure 6b ). Because the induction of Nur77 and Nor1 by ionomycin involves the release of the CabinI/ HDACs complex from gene promoters, 39 we tested the effect of pretreatment of SNDX-275 on ionomycin-induced Nur77/Nor1 expression and apoptosis. Combined use of SNDX-275 dramatically increased the ionomycin-induced Nur77 and Nor1 proteins in HL-60 and induced a significantly higher degree of apoptosis than ionomycin alone (Figures 6a and b) . Similarly, the combination of ionomycin and SNDX-275 induced high levels of Nur77 and Nor1 in OCI-AML3 and Nur77 in AML9 cells, respectively, accompanied by increased apoptosis as compared to ionomycin or SNDX-275. Most importantly, apoptosis induced by SNDX-275 and ionomycin was attenuated by silencing Nur77/Nor1 (Figures 6c and d) . This observation supported the notion of a functional role of Nur77/nor1 in apoptosis induction of AML cells and suggested an additive activation mechanism in Nur77/Nor1 expression. Surprisingly, SiMix does not have significant effects on apoptosis induced by ionomycin alone, suggesting that Nur77/Nor1 may not have functional roles in ionomycin-induced apoptosis. Altogether, these findings suggest that apoptosis induced by SNDX-275 is mediated at least in part by the restoration of Nur77 and Nor1 function; however, additional mechanisms are likely operational in AML cells.
SNDX-275 induces pro-apoptotic proteins Bim and Noxa SNDX-275 induces apoptosis in tumor cells by a variety of different mechanisms, for example, inducing Bim and Noxa in chronic lymphocytic leukemia. 40 We sought to characterize the contribution of the mitochondrial apoptotic pathway in SNDX-275-induced apoptosis, in particular through the pro-apoptotic Bcl2 family members Bim and Noxa. Real-time reverse transcription PCR analysis and western blotting showed that both Bim and Noxa were elevated by the compound in AML cell lines and primary samples, in association with caspase 9 cleavage (Figures 7a-c) . Besides, these elevations are not dependent on Nur77/Nor1 restoration (Supplementary Figures 2B and 3D-F) . We confirmed the role of Noxa and Bim in SNDX-mediated apoptosis with siRNA gene silencing. SiNoxa led to reduction of SNDX-275-induced gene upregulation and this resulted in significantly diminished SNDX-275-induced apoptosis in HL-60 cells (Figure 7d ) and two primary AML samples (Figures 7e and f) . SiBim also significantly protected HL-60 cells and primary AML cells from Figure 4) . Our observation suggests that SNDX-275-induced upregulation of pro-apoptotic BH3-only Bcl2 members in AML likely contributes to its pro-apoptotic activity.
SNDX-275-induced apoptosis (Supplementary
SNDX-275 induces apoptosis in AML stem cells (CD34
AML is a disease of hematopoietic stem cells and progenitors cells, and relapse after chemotherapy is thought to originate from an outgrowth of LSCs, a population of malignant CD34 þ CD38 À progenitor cells. In our previous study, we observed the universal downregulation of Nur77 and Nor1 gene expression in primary AML blasts. 2 Here we measured the expression profiles of Nur77 and Nor1 in putative AML stem cells defined as CD34 þ /38 À . Our results demonstrated the remarkable downregulation of both Nur77 and Nor1 transcripts in LSCs (CD34 þ /38 À ), as well as in myeloid progenitor cells (CD34 þ /38 þ ) and in committed progenitor cells (CD33 þ /34 À ) (Figure 8a ). We next evaluated the effects of SNDX-275 on LSCs. Our results demonstrated that SNDX-275 remarkably reduced the viable cell numbers and induced apoptosis in the LSC fraction of primary AML samples (Figure 8b) . Gene-expression analysis revealed that in the CD34 þ /38 À population, SNDX-275 restored Nur77 and Nor1 and induced c-Jun, TRAIL, Bim and Noxa (Figure 8c ).
DISCUSSION
We here extend our previous observation of silencing of Nur77 and Nor1 in AMLs to leukemic stem/progenitor cells and demonstrate that blockade of histone deacetylation by HDAC inhibitor SNDX-275 efficiently restores Nur77/Nor1 expression in AML cells and LSCs and induces apoptosis. The induction of Nur77 and Nor1 involves the hyperacetylation of their promoters. To our knowledge, our current report is the first to describe the restoration of Nur77 and Nor1 by HDAC inhibition in AML. These findings implicate histone deacetylation as an important mechanism of Nur77 and Nor1 silencing in AML, and suggest that Nur77 and Nor1 have an important role in survival and proliferation of leukemic cells.
Restoration of Nur77 and Nor1 and apoptosis induction by HDAC inhibition has been reported in cutaneous T-cell lymphomas 41 involving a mechanism mediated by HDAC7, a class IIA HDAC that represses Nur77 expression in thymocytes/ lymphocytes. 42, 43 We attempted identification of HDAC7 in several myeloid leukemic cell lines (HL-60, MOLM13 and OCI-AML3) but its expression was below detectable at both mRNA or protein levels (data not shown), implying tissue specificity of this mechanism. Recently, it was reported that Nur77 expression is also regulated at the posttranscriptional level by acetylation, and HDAC1 mediated its deactivation leading to ubiquitination. 44 With its specificity on class I HDACs (including HDAC1, 2 and 3), SNDX-275 might restore gene expression at both transcriptional and posttranscriptional levels. In the context of our study, SNDX-275 regulated Nur77 and Nor1 gene expression mainly at the transcriptional level, because treatment with SNDX-275 only did not induce pronounce induction of proteins. However, the causeeffect relationship between gene induction and apoptosis is unequivocal (Figures 5 and 6) . Recently, bifunctional RNA has been identified in many species from bacteria to mammals: RNA contains both coding capacity and regulatory activity. 45 Steroid receptor RNA, with a long ORF and no initiating methionines, has been shown to co-regulate with the progesterone and several Figure 6 . Silencing of nur77 and nor1 suppresses apoptosis induced by the combination of SNDX-275 and ionomycin. AML cell lines HL-60 and OCI-AML3, and one primary AML sample were pretreated with SNDX-275 (0.5, 1 and 1 mM, respectively) for 16 h followed by treatment with ionomycin (1 mg/ml). Protein lysates were collected at 6 h after ionomycin treatment for detection of Nur77/Nor1 protein (a), and apoptosis induction was analyzed at 48 h (b). HL-60 transfected with scrambled siRNA (Scr), siRNA or a mixture of SiNur77 and SiNor1 (SiMix) were pretreated with 0.5 mM SNDX-275 followed by 1 mg/ml ionomycin. Protein lysates were collected at 6 h after ionomycin treatment for detection of Nur77/Nor1 protein (c), and apoptosis induction was analyzed at 48 h (d).
other steroid receptors; 46 p53 mRNA was shown to interact with Mdm2 protein to prevent Mdm2 from promoting p53 protein ubiquitination and degradation and ultimately to stimulate p53 synthesis. 47, 48 Although such effects are speculative in the context of our work, they are nevertheless a distinct possibility and could explain functionality without direct protein synthesis. In addition, histone deacetylation may not be the only mechanism responsible for Nur77 and Nor1 silencing, which was implied by the ionomycin combination experiment, and HDAC inhibiton as a single treatment may not be sufficient to restore silenced gene expression completely. Still, reactivation is a vital step in overcoming gene silencing.
We have demonstrated that restoration of Nur77 and Nor1 was associated with c-Jun and JunB induction and that silencing Nur77 and Nor1 significantly prevented c-Jun and JunB upregulation in HL-60. This effect, however, were not consistently observed in primary AML samples. This discrepancy may be explained by alternative mechanisms regulating expression of these transcription factors in primary samples. Furthermore, multiple activator protein 1-like binding sites were identified in the Nur77 promoter. 49 However, silencing of c-Jun with siRNA did not affect upregulation of Nur77/Nor1 by SNDX-275 (data not shown). Further studies to delineate the hierarchical relations of Jun transcription factors and Nur77/Nor1 are clearly warranted. Similarly, our findings indicate that TRAIL may not be a direct target of Nur77/Nor1.
The induction of pro-apoptotic BH3-only proteins Noxa and Bim contributes to SNDX-275-induced apoptosis in AML, indicating involvement of the mitochondrial apoptosis pathway in addition to TRAIL-mediated activation of extrinsic apoptotic signaling. In contrast to a published observation, 50 we did not observe modulation of Bcl2 protein expression by SNDX-275 (data not shown). NR4As have also been implicated in the regulation of apoptosis via mechanisms independent of their primary transcription regulatory function, via translocation to mitochondria and interaction with the antiapoptotic protein, BCL2, leading to NR4A-dependent conversion of BCL2 into a proapoptotic mediator. 8, 51 The relative contribution of genomic versus non-genomic mechanisms of apoptosis induction in leukemic cells remains to be established. Targeting LSCs remains the key for eradicating persistent leukemia. The consistent downregulation of leukemia suppressors Nur77 and Nor1 among subpopulations reinforces that the silencing of these genes is a common event in AML cells, irrespective of the differentiation status, and that it is a critical step in leukemogenesis. In our present report, we demonstrate that SNDX-275 restores the expression of Nur77 and Nor1 in LSCs and induces cell death in these cells. The restoration of Nur77 and Nor1, their relative genes and the induction of pro-apoptotic genes in LSCs may explain how SNDX-275 kills LSCs. Our results strongly suggest the potential ability of SNDX-275 to affect LSCs. This would endow SNDX-275 with the capacity to kill not only bulk leukemic cells but also leukemia-initiating cells.
In conclusion, our findings suggest that HDAC-mediated gene silencing of the nuclear receptors Nur77 and Nor1 is a novel mechanism critical for survival of AML blasts and stem cells. Reexpression of these nuclear receptors may be considered as a valuable biomarker for the ability of HDAC inhibitors to induce apoptosis of LSC. We propose that therapeutic approaches directed toward the reexpression/activation of Nur77 and Nor1 could be of significant benefit in the treatment of human AML, irrespective of karyotype. To this aim, further understanding of the mechanism of Nur77/Nor1 silencing in AML and the exploration of alternative mechanisms other than histone deacetylation would provide clues for drug combination in leukemia therapy.
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